{"database": "lobbying", "table": "lobbying_activities", "rows": [[3197861, "c9457a43-17a3-4efe-84b5-8b5a5b950ed9", "Q2", "MEHLMAN CONSULTING, INC.", 284950, "THE CAMPAIGN FOR SUSTAINABLE RX PRICING", 2024, "second_quarter", "PHA", "Prescription drug pricing issues. S. 2305 - Biosimilar Red Tape Elimination Act. S. 148 - Stop Significant and Time-Wasting Abuse Limiting Legitimate Innovation of New Generics Act. S. 1067 - Ensuring Timely Access to Generics Act. S. 775/H.R. 3839 - Increasing Transparency in Generic Drug Applications Act. S. 1214 - Retaining Access and Restoring Exclusivity (RARE) Act.", "Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE", 50000, null, 0, 0, "2024-07-18T09:58:12-04:00"]], "columns": ["id", "filing_uuid", "filing_type", "registrant_name", "registrant_id", "client_name", "filing_year", "filing_period", "issue_code", "specific_issues", "government_entities", "income_amount", "expense_amount", "is_no_activity", "is_termination", "received_date"], "primary_keys": ["id"], "primary_key_values": ["3197861"], "units": {}, "query_ms": 58.375712018460035, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}